The Objectives

• Refine Ublituximab’s value proposition through real-world market insights
• Develop stakeholder-specific messaging for payers, providers, and decision-makers
• Craft a pricing strategy backed by clinical data and HEOR modeling
• Ensure alignment between market expectations and regulatory requirements
• Position Ublituximab as a high-value therapeutic with clear clinical and economic justification

The Strategy

We partnered closely with Precision for Value’s internal teams to execute a multi-phased strategic framework—merging health economics, stakeholder intelligence, and differentiated positioning.

Phase 1: Value Discovery & Market Insights

We began with an extensive analysis of the competitive landscape, mapping current therapies, payer expectations, and unmet patient needs.

🔬 Deep-dive HEOR and real-world outcomes modeling

📊 Competitive benchmarking to identify clinical and economic differentiators

🎯 Stakeholder mapping to tailor messaging to different decision-maker types (e.g., HTA bodies, hospital systems, specialist networks)

We identified Ublituximab’s unique selling points: streamlined administration, safety profile, and promising efficacy—all critical for market entry and payer alignment.

Phase 2: Evidence-Based Pricing Strategy

We developed a tiered pricing model, accounting for international reference pricing, treatment cost comparisons, and projected quality-adjusted life years (QALY) impact.

• Scenario-based pricing forecasts across EU5, US, and emerging markets
• Adaptable pricing playbooks designed for both private and public payer systems
• Frameworks to support payer negotiations, including total cost-of-care impact models

Creative Highlights

• 📄 Executive-facing value dossiers with clinical, HEOR, and economic data visualization
• 🧾 Slide decks and payer briefings: “Ublituximab’s Place in Therapy”
• 📊 Cost-offset calculators comparing therapy duration and hospitalization rates
• 🧠 Messaging grids tailored to KOLs, payers, and regulatory authorities
• 🌐 Market-ready tools to support launch sequencing by geography

The Impact

Orchidea helped Precision for Value move Ublituximab from pipeline to payline—by building a strategy grounded in evidence, tailored to real-world decision-makers, and adaptable across global markets.

This engagement demonstrated how smart, data-driven positioning can turn clinical promise into healthcare reality—where innovation is matched with access.

Because in healthcare, value isn’t just what you say—it’s what you prove.